To Our New Jersey Life Sciences Community:
Welcome to another edition of The Weekender.
Let’s start the good news with another FDA approval in 2015, shall we?
Congratulations to Actavis for its approval of AVYCAZ, a treatment for adult patients with complicated intra-abdominal infections and complicated urinary tract infections.
This week’s excitement continues with the release of GEN’S (Genetic Engineering & Biotechnology News) Top 10 U.S. Biopharma Clusters List, placing New Jersey in the #3 spot. The Garden State/Empire State tandem is the leader in jobs (77,645 according to JLL) and lab space (20.6 million square feet), reflecting its status as having the nation’s largest region, numerous research institutions and a sizable heritage pharma industry. This recognition continues to demonstrate how robust the New Jersey ecosystem is. With continued dedication, the industry in our state will only continue to grow.
Also in the news, the FDA approved the first biosimilar, changing the landscape of our industry as we know it. Zarzio from Sandoz, a drug treatment for chemotherapy patients, is the first drug approved under this new regulatory framework.
CLick here for this week’s Weekender.